Clinical Trial

A Study of Guselkumab Treatment Persistence in Psoriatic Arthritis Participants

Study acronym: PEGASUS
Recruiting
View on ClinicalTrials.gov →
Summary
This observational study aims to assess the 1-year persistence of guselkumab in adult patients with psoriatic arthritis (an inflammatory disease that affects the joints in participants with psoriasis, a skin condition that causes red, scaly patches).
Protocol Amendment History 1 change
critical Recruitment opened 2026-05-13
Trial Details
NCT Number NCT07532226
Lead Sponsor Janssen-Cilag Ltd.
Conditions Arthritis, Psoriatic
Enrollment 200 participants
Start Date 2026-04-17
Primary Completion 2029-12-10 (estimated)
Study Completion 2029-12-10 (estimated)
Updated on ClinicalTrials.gov 2026-07-06